参考文献/References:
[1] Morris SW,Kirstein MN,Valentine MB.Fusion of a kinase gene,ALK,to a nucleolar protein gene,NPM,in non-Hodgkin's lymphoma[J].Science,1994,263(5151):1281-1284.
[2] Cazzola M.Introduction to a review seties:The 2016 revision of the WHOclassification of tumors of bematopietic and lymphoid tissues[J].Blood,2016,127(20):2361-2364.
[3] Gorczynski A,Prelowska M,Adam P,et al.ALK-positive cancer:still a growing entity[J].Future Oncol,2014,10(2):305-321.
[4] Gascoyne RD,Lamant L,Martin-Subero JI,et al.ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements:report of6 cases[J].Blood,2003,102(7):2568-2573.
[5] Wass M,Behlendorf T,Schaedlich B,et al.Crizotinib in refractory ALK-positive large-cell lymphoma:a case report with a short-term response[J].Eur J Haematol,2014,92(3):268-270.
[6] Soda M,Choi YL,Enomoto M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J].Nature,2007,448(7153):561-566.
[7] 曹培龙,王 凯,王鸿雁,等.ALK阳性非小细胞肺癌72例临床病理分析[J].临床与实验病理学杂志,2017,33(10):1092-1096.
Cao PL,Wang K,Wang HY,et al.Non-small cell lung cancer with EML4-ALK positive expression:a clinicopathological analysis of 72 cases[J].J Clin Exp Pathol,2017,33(10):1092-1096.
[8] 黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(5):16-18,23.
Lixie MD,Luo K,Wu SF,et al.Mutation analysis of EGFR,ALK and ROS1 in tumor tissues of patient with non-small cell lung cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(5):16-18,23.
[9] National Comprehensive Cancer Network(NCCN).Clinical Practice Guidelinesin Oncology.Non-Small Cell Lung Cancer,Version 2,2017.
[10] Viala M,Brossau S,Planchard D,et al.Second generation ALK inhibitors in non-small cell lung cancer:systemic review[J].Bull Cancer,2015,102(4):381-389.
[11] Ou SH,Jannoe PA,Bartlett CH,et al.Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients withadvanced ALK-positive NSCLC[J].Ann Oancol,2014,25(2):415-422.
[12] Friboulet L,Li N,Kaiayama R,et al.The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung[J].Cancer Discov,2014,4(6):662-673.
[13] Kodama T,Tsukaguchi T,Yoshida M,et al.Selective ALK inbibitor alectinib with potent antitumor activity in models of crizotinib resistance[J].Cancer Lett,2014,351(2):215-221.
[14] Schulte JH,Schulte S,Heukamp LC,et al.Targeted therapy for neuroblastoma:ALK inhibitors[J].Klin Padiatr,2013,225(6):303-308.
[15] Shi H,Wei L,Sun L,et al.Prinary gastrie inflammatory myofibroblastictumor:a clinicopathologic and immunohistochemical study of 5 eases[J].Pathol Res pract,2010,206(5):287-291.
[16] Antonescu CR,Suurmeijer AJ,Zhang L,et al.Molecular characterizationof inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement[J].Am J Surg Pathol,2015,39(7):957-967.
[17] Butrynski JE,D'Adamo DH,Hornick JL,et al.Crizotinib in ALK-raerranged inflammatory myofibroblastic tumor[J].N Engl J Med,2010,363(18):1727-1733.
[18] Lamant L,Pulford D,Bischof D,et al.Expression of the ALK tyrosine kinase gene in neuroblastoma[J].2000,156(5):1711-1721.
[19] Wang M,Zhon C,Sun Q,et al.ALK amplification and protein expression prediet inferior prognosis in neuroblastoma[J].Exp Mol Pathol,2013,95(2):124-130.
[20] Busam KL,Kutzner H,Cerroni L,et al.Clinical and pathologic findingsof spitz nevi and atypical spitz tumors with ALK fusions[J].Am J Surg Pathol,2014,38(7):925-933.
[21] Lin E,Li L,Guan Y,et al.Exon array profiling detests EML4-ALK fusion in breast,colorectal,and non-small cell lung cancers[J].Mol Cancer Res,2009,7(9):1466-1476.
[22] Ren H,Tan ZP,Zhu X,et al.Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovrtion cancer[J].Cancer Res,2012,72(13):3312-3323.
[23] Lee C,Park JW,Suth JH,et al.ALK-Positive renal cell carcinoma in alarge serise of consecutively resected Korean renal cell carcinoma patients[J].Korean J Pathol,2013,47(5):452-457.
[24] Jazii FR,Najafi Z,Malekzadeh R,et al.Identification of squamous cellcarcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer[J].World Cancer Gastroenterol,2006,12(44):7104-7122.
[25] Murugan AK,Xing M.Anaplastic thyrorid cancers harbor novel oncogenic mutations of the ALK gene[J].Cancer Res,2011,71(13):4403-4411.
[26] Chou A,Fraser S,Toon CW,et al.A detailed clinicopathologie study ofALK-translocated papillary thyroid carcinoma[J].Am J Surg Pathol,2015,39(5):652-659.
[27] Kim SML,Kim MJ,Jung HA,et al.Presence of anaplastic lymphoma kinasetranslocation in sarcomatoid carcinoma of head and neck and treatment effect ofcrizotinib:A case series[J].Head Neek,2015,37(5):E66-E69.
[28] Chiarle R,Gong JZ,Guasparri I,et al.NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors[J].Blood,2003,101(5):1919-1927.
[29] 宋蓉蓉,任国平,刘晓燕,等.前列腺癌间变性淋巴瘤激酶基因改变与蛋白表达及其临床意义[J].中华病理学杂志,2015,44(6):382-385.
Song RR,Ren GP,Liu XY,et al.Alterations of ALK gene and protein expression in prostatic cancer and its clinical significance[J].Chinese Journal Pathology,2015,44(6):382-385.
[30] 刘建化,金浩生,田红霞,等.HBsAg阳性肝癌患者预后及病理因素与ALK基因表达的相关性研究[J].中国病理生理杂志,2016,32(5):841-846.
Liu JH,Jin HS,Tian HX,et al.Status and clinical siguificance of ALK gene expression in HBsAg-positive hepatocellular carcinoma patients[J].ChineseJournal of Pathophysiology,2016,32(5):841-846.